In one of the ongoing trials, patients with metastatic cancer positive for mesothelin (including mesothelioma, ovarian, cervical, lung and pancreatic tumors) undergo lymphodepleting conditioning with cyclophosphamide and fludarabine, followed by intravenous infusion of ex vivo engineered, anti-mesothelin CAR expressing T cells plus low dose IV Interleukin-2 (ClinicalTrials.gov Identifier: NCT01583686). The gene discussed is MSLN; the disease is mesothelioma.